LLY
738.06
+1.61%↑
JNJ
178.12
-0.03%↓
ABBV
209.99
-1.09%↓
UNH
320.2
+1.63%↑
NVO
54.31
-1.47%↓
LLY
738.06
+1.61%↑
JNJ
178.12
-0.03%↓
ABBV
209.99
-1.09%↓
UNH
320.2
+1.63%↑
NVO
54.31
-1.47%↓
LLY
738.06
+1.61%↑
JNJ
178.12
-0.03%↓
ABBV
209.99
-1.09%↓
UNH
320.2
+1.63%↑
NVO
54.31
-1.47%↓
LLY
738.06
+1.61%↑
JNJ
178.12
-0.03%↓
ABBV
209.99
-1.09%↓
UNH
320.2
+1.63%↑
NVO
54.31
-1.47%↓
LLY
738.06
+1.61%↑
JNJ
178.12
-0.03%↓
ABBV
209.99
-1.09%↓
UNH
320.2
+1.63%↑
NVO
54.31
-1.47%↓
24h
Current
Min
10.17
Max
10.76
Income | 26M -26M |
---|---|
Sales | 2.1M 2.1M |
Profit margin | -1,213.57 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +39.28% upside |
Next Earnings | 4 lis 2025 |
---|
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
8 maj 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 gru 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15 USD 39.28%
High 20 USD
Low 13 USD
Based on 5 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
5 ratings
5
Buy
0
Hold
0
Sell
Based on 5 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$